Trametinib

Drug #2313

Trametinib dimethyl sulfoxide is a kinase inhibitor. The chemical name is acetamide, N-[3-[3 234 cyclopropyl-5-[(2-fluoro-4- iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl- 2,4,7 235 trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]-, compound with 1,1’-sulfinylbis[methane] (1:1). It is used in the treatment of patients with unresectable or metastatic Melanoma with BRAF V600E or V600K mutations.

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin and belongs to pyridopyrimidines..

It belongs to Protein kinase inhibitor pharmacological group on the basis of mechanism of action.

Molecular Weight: 693.53 · Non-proprietary name: Trametinib.

Pharmacokinetics

Absorption: Trametinib has an oral bioavailability is 72%.

Distribution: Trametinib has a volume of distribution is 241L. plasma protein binding is 97.4%.

Elimination: it is metabolised via hepatic, plasma half-life is 3.9-4.8, renal excretion is 80% by feces, 20% by urinr.

Indications

Trametinib is primarily indicated in conditions like Metastatic melanoma, Metastatic melanoma.

Contraindications

None recorded.

Dosage

Trametinib's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
2 mg	2 mg	—	PO	one hour before or at least 2 hrs after a meal.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

None recorded.

Side Effects

Trametinib is known to cause more or less tolerable side effects which are usually transient. These include Diarrhea, lymphedema, Rash.

Warnings / Precautions

cardiomyopathy, Retinal Pigment Epithelial Detachment, retinal Vein Occlusion, Interstitial Lung Disease, Serious Skin Toxicity, Embryofetal toxicity

Available Brands

None recorded.

Storage Conditions

Trametinib should be stored Film Coated Tablet.

Drug Classification

1.8.2 — Cytotoxic (anti-neoplastic) drugs